Program
NNC0519-0130
A development code. Also written as “NNC0519-0130 B” and “NNC0519-0130 C”.
In Novo Nordisk's own words, a once-weekly GIP/GLP-1 co-agonist (NNC0519-0130)
. Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Renal Insufficiency, Chronic · Diabetes Mellitus, led by Novo Nordisk.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 111 open or running | phase 2since Mar 16, 2024 | Apr 18, 2022 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 18, 2022First study: phase 1 study in Diabetes MellitusFirst studyNCT05363774 · 161 enrolled · Denmark, Germany
- May 12, 2023Phase 1 study in Diabetes Mellitus, Type 2NCT05870670 · 22 enrolled · Japan
- Mar 16, 20242 phase 2 studiesNCT06326060, NCT06326047
- Apr 12, 2024Phase 1 study in Diabetes Mellitus, Type 2NCT06370819 · 36 enrolled · Germany
- Jul 16, 2024Phase 1 study in Diabetes Mellitus, Type 2NCT06513104 · 47 enrolled · Germany
- Aug 20, 2024Phase 1 study in Diabetes Mellitus, Type 2NCT06567041 · 82 enrolled · Germany
- Oct 13, 2024Phase 1 study in ObesityNCT06642571 · 46 enrolled · United States
- Nov 30, 2024Phase 2 study in Renal Insufficiency, ChronicNCT06717698 · 465 planned · United States, Argentina, Australia and more
- Dec 2, 2024Phase 1 study in ObesityNCT06718998 · 134 enrolled · Austria
- May 26, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT07004322 · 20 enrolled · China
TargetBeta
“a once-weekly GIP/GLP-1 co-agonist (NNC0519-0130)”company filing, read by Claude · source
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| olatorepatide | Hansoh Pharmaceutical Group | phase 3 | 12 |
| UBT251 | The United Laboratories International | phase 3 | 12 |
| enicepatide | Hoffmann-La Roche | phase 3 | 10 |
| VK2735rule | Viking Therapeutics | phase 3 | 8 |
| BI 3034701 | Boehringer Ingelheim | phase 2 | 6 |
| HRS-4729 | Jiangsu HengRui Medicine | phase 2 | 5 |
| NA-931rule | biomed-industries-inc | phase 2 | 3 |
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07004322Diabetes Mellitus, Type 2 · China | 1 | Completed | Jan 28, 2026 | 20 |
| NCT06718998Obesity · Austria | 1 | Completed | Jan 12, 2026 | 134 |
| NCT06717698Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 2 | Recruiting | Sep 1, 2026 | 465 |
| NCT06642571Obesity · United States | 1 | Completed | May 17, 2025 | 46 |
| NCT06567041Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Dec 10, 2025 | 82 |
| NCT06513104Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Sep 10, 2025 | 47 |
| NCT06370819Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Nov 27, 2024 | 36 |
| NCT06326060Obesity · United States, Australia, Japan | 2 | Completed | Apr 10, 2025 | 354 |
| NCT06326047Diabetes Mellitus, Type 2 · United States, Australia, Canada and more | 2 | Completed | Sep 19, 2025 | 299 |
| NCT05870670Diabetes Mellitus, Type 2 · Japan | 1 | Completed | Oct 7, 2023 | 22 |
| NCT05363774Diabetes Mellitus · Denmark, Germany | 1 | Completed | Apr 2, 2024 | 161 |
How it is read
Names in the registry
- “NNC0519-0130”, 10 entries
- “NNC0519-0130 B”, 1 entry
- “NNC0519-0130 C”, 1 entry
Codes read as this program: NNC05190130.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 6 studies
- Obesity, 3 studies
- Renal Insufficiency, Chronic, 1 study
- Diabetes Mellitus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.